Nick Plugis, Avak Kahvejian, Cristina Rondinone, Milind Kamkolkar and Chad Nusbaum. (Cellarity)

December 10, 2019 10:28 AM ESTUpdated December 18, 09:59 AM

Cellarity, Flagship's $50M bet on network biology, marries machine learning and single-cell tech for drug discovery

Amber Tong

Cellarity started with a simple — but far from easy — idea that Avak Kahvejian and his team were floating around at Flagship Pioneering: to digitally encode …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cellarity, Flagship's $50M bet on network biology, marries machine learning and single-cell tech for drug discovery

Amber Tong

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Netherlands pours $1.5B into biotech in pursuit of global leadership ambitions

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Cel­lar­i­ty, Flag­ship's $50M bet on net­work bi­ol­o­gy, mar­ries ma­chine learn­ing and sin­gle-cell tech for drug dis­cov­ery

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Cellarity, Flagship's $50M bet on network biology, marries machine learning and single-cell tech for drug discovery